ClinicalTrials.gg
Active, not recruitingNCT04969471NATUREUpdated Aug 19, 2026

NATURE (EnVast as an Adjunct PPCI in Subjects Presenting With STEMI)

An interventional study of enVast stent and conventional treatment in Segment Elevation Myocardial Infarction (STEMI), sponsored by Vesalio. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Primary conditionST Elevation Myocardial InfarctionRegistry: Myocardial InfarctionReclassifiedWhy we changed it
Registry
Myocardial Infarction — the first condition term the registry derived for this study.
ClinicalTrials.gg
ST Elevation Myocardial Infarction
Why
  1. The study's listed conditions name ST Elevation Myocardial Infarction, a narrower term within Myocardial Infarction.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Vesalio · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in ST Elevation Myocardial Infarction with a site in Italy — 14 open to participants now, 17 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Italy.

Planned enrollment
22nd of 42
148 · median 174
Started
2021
with 1 other
No phase
17 of 71
5 open now
Primary completion
2026-06
later than 7 of 16 live
Registered
52nd of 71
by date

Among the 71 studies in ST Elevation Myocardial Infarction with a site in Italy, this one is the 22nd largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2021, is one of 17 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 52nd registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

14 of the 71 studies in ST Elevation Myocardial Infarction with a site in Italy are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in ST Elevation Myocardial Infarction with a site in Italy, or all of them as a file.
02

Study summary

This study is designed to compare the safety and effectiveness of blood clot (thrombus) removal in subjects presenting with ST-segment elevation myocardial infarction (STEMI) with the enVast coronary system versus conventional intervention.

Read the detailed description

A prospective, multi-center, randomized clinical trial designed to assess the safety and effectiveness of the enVast coronary thrombectomy system as an adjunctive measure to conventional intervention in subjects presenting with ST-segment elevation myocardial infarction (STEMI).

03

Conditions studied

  • Segment Elevation Myocardial Infarction (STEMI)

Browse trials for

04

In context

ST Elevation Myocardial Infarction Reclassified

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

This study's planned enrollment of 148 is below the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

Vesalio is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Compared within ST Elevation Myocardial Infarction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Infarction. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Chest pain for > 20 min with an electrocardiographic ST-segment elevation ≥ 1 mm in two or more contiguous (ECG) leads or an infero-lateral myocardial infarction (MI) with ST segment depression of ≥ 1 mm in ≥ 2 of leads V1-3 with a positive terminal T wave.
  3. TIMI Thrombus Grade ≥ 3 in the infarct related artery. In cases where TIMI Thrombus Grade is equal to 5 (i.e. TIMI 0 flow in the infarcted artery), TIMI Thrombus Grade of at least 3 has to be re-confirmed with AWI. Patients showing TIMI Thrombus Grade of less than 3 upon AWI are no longer eligible for randomization.
  4. Start of intervention within 8 h of symptom onset
  5. Subject is willing and able to provide prior to the intervention

Exclusion criteria

Exclusion Criteria:

  1. Unconscious patients
  2. Infarct related artery diameter, at visual assessment, smaller than 2.5 mm
  3. Presence of severely calcified plaque(s) proximal to or at the site of the culprit lesion(s)
  4. Presence of extreme vessel tortuosity proximal to or at the site of the culprit lesion(s)
  5. Women of (e.g. below 55 years of age, who have not undergone tubal ligation, ovariectomy or hysterectomy and last menstruation within the last 12 months)
  6. Stent thrombosis as culprit lesion
  7. Previous myocardial infarction in the same territory (i.e. same target vessel)
  8. Participation in another interventional clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Thrombectomy Arm

    enVast stent deployed at occlusion site as first measure to obtain reperfusion and withdraw the clot

    Device: enVast stent

  • Experimental
    Conventional Treatment Arm

    Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.

    Procedure: conventional treatment

Interventions

  • DeviceenVast stent

    In addition to conventional treatment, the treating physician will deploy as the first measure to obtain reperfusion, a enVast stent at the occlusion site in order to withdraw the clot.

  • Procedureconventional treatment

    Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.

07

What researchers measure

Primary outcomes

  1. Infarct size

    size assessed by measurements of CK-MB (U/L)

    Time frame: At 3 days

Secondary outcomes

  1. MRI core lab Infarct size outcome

    Infarct size (% of LV mass)

    Time frame: At 3 days

  2. CK

    AUC for CK

    Time frame: at 3 days

  3. hsTroponin T

    AUC for hsTroponin T

    Time frame: at 3 days

  4. ECG core lab outcome measures

    The cumulative ST-segment deviation/elevation resolution and residual ST-segment elevation (calculated as the sum in mm of any ST-elevation and depression)

    Time frame: At Procedure

  5. Angio core lab TIMI Flow

    TIMI flow

    Time frame: At Procedure

  6. Echo core lab LVEF outcome measures

    Left ventricular ejection fraction (LVEF)

    Time frame: At discharge (an average of 3 days)

  7. BNP

    Kinetics of B-type natriuretic peptide/NT proBNP

    Time frame: At discharge (an average of 3 days)

  8. Diuretic treatment

    Need for diuretic treatment

    Time frame: At discharge (an average of 3 days)

  9. Histopathology

    Histopathological evaluation of the retrieved thrombotic material (if feasible)

    Time frame: During procedure

  10. Additional MRI analysis

    Additional analyses will include the assessments of hemodynamic forces and radiomics at MRI

    Time frame: At procedure

  11. Primary safety endpoint

    MACE

    Time frame: Day 3

  12. CEC outcome measures

    SAEs will be described according to severity and to their relationship with the study device and procedure.

    Time frame: at 1-year follow-up

  13. Other important safety endpoints

    The composite of CV death, MI, and any CVA, including TIA/stroke; Death from CV causes; Overall death as stand-alone endpoint and in combination with MI, and/or CVA; Definite or probable stent thrombosis; New onset cardiogenic shock requiring inotropes or mechanical assist device; MI; Any stroke, any ischemic stroke with or without TIA; Bleeding events (access site or non-access site related) according to the BARC classification; Rehospitalization for HF in isolation and in association with CV death and/or, resuscitated cardiac arrest or ICD implantation at follow-up; Bailout use of parenteral anti-platelet agents (GPI or cangrelor) defined as any use during or after the procedure in subjects in whom no intention to use a parenteral anti-platelet agent was declared at the time of randomization; Any urgent or non-urgent TVR

    Time frame: throughout 1-year follow-up

  14. MRI Core Lab myocardial salvage index

    myocardial salvage index

    Time frame: At 3 days

  15. MRI Core Lab microvascular obstruction outcome

    microvascular obstruction

    Time frame: At 3 days

  16. MRI Core Lab LV volume outcome

    LV volume

    Time frame: At 3 days

  17. MRI Core lab intramyocardial haemorrhage outcome

    intramyocardial hemorrhage

    Time frame: At 3 days

  18. MRI core Lab left ventricle and right ventricle thrombosis outcome

    left ventricle and right ventricle thrombosis

    Time frame: At 3 days

  19. MRI Core Lab RV function outcome

    RV function assessment

    Time frame: At 3 days

  20. Core lab T2 mapping of the left ventricle

    T2 mapping of the left ventricle

    Time frame: At 3 days

  21. MRI Core Lab wall motion score index

    wall motion score index

    Time frame: At 3 days

  22. Angio Core Lab Corrected TIMI frame count

    Corrected TIMI frame count

    Time frame: At Procedure

  23. Angio Core Lab Myocardial Blush Grade

    Myocardial Blush Grade

    Time frame: At Procedure

  24. Echo Core Lab LV volume

    LV volume

    Time frame: 12 months

  25. Echo Core Lab wall motion score index

    wall motion score index,

    Time frame: 12 months

  26. Echo Core Lab wall thickness

    wall thickness

    Time frame: At discharge (an average of 3 days)

  27. Echo Core lab myocardial deformation Outcome

    Myocardial deformation

    Time frame: At discharge (an average of 3 days)

  28. Echo Core lab right ventricle function assessment

    Right ventricle function

    Time frame: At discharge (an average of 3 days)

08

Study locations

11 sites
09

References and documents

Publications

  • Landi A, Biscaglia S, Cuculi F, Erriquez A, Bossard M, Colombo A, Mangieri A, Meuwissen M, Iglesias JF, Sangiorgi G, Lipsic E, Oreglia JA, Haner JD, Paradies V, Crimi G, Milzi A, Pavon AG, Leo LA, Frigoli E, Valgimigli M. The use of mechanical thrombectomy in patients with STEMI and large thrombus burden: design and rationale of the NATURE trial. Cardiovasc Revasc Med. 2026 Mar 4:S1553-8389(26)00082-5. doi: 10.1016/j.carrev.2026.03.002. Online ahead of print. PubMed 41820070 ↗

Individual participant data

Plan to share: Yes — Deidentified individual participant data underlying the primary and secondary efficacy and safety endpoints reported in this article (CK-MB AUC, CMR measures, biomarkers, electrocardiographic and angiographic outcomes, adverse events), after removal of direct and indirect identifiers.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Beginning 12 months (due to ongoing 12-month data collection) and ending 36 months following article publication

Access criteria: With researchers who provide a methodologically sound proposal, reviewed and approved by an independent scientific review committee, to achieve the aims of the approved proposal, via a signed data access agreement, to achieve the aims of the approved proposal, via a signed data access agreement. Proposals should be directed to [datasharing@vesalio.com]. Data requestors will be required to submit a methodologically sound research proposal; requests will be reviewed by Vesalio to confirm consistency with the aims of the approved proposal. Approved requestors will be required to sign a data access agreement prior to receiving deidentified data, which will be made available through a Vesalio-managed secure data portal

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jun 2026, 53 months.

Of 145 interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2021
First posted
Jul 20, 2021
StartActual
Dec 9, 2021
Primary completionActual
Jun 1, 2026
CompletionEst.
Aug 1, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04969471
Lead sponsor
Vesalio
Responsible party
Sponsor
First posted
Jul 20, 2021
Start date
Dec 9, 2021
Primary completion
Jun 1, 2026
Completion
Aug 1, 2027 (estimated)
Last update
Aug 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion